Research

To date, clinical evidence supporting the efficacy of cannabis for PTSD has been positive in nature but weak in power; hopefully stronger clinical evidence will be forthcoming.

Gb Sciences, recently announced positive results from a study of its cannabinoid-containing mixtures as a potential treatment for cytokine release syndrome (CRS). With the high rate of transmission of the Omicron variant in multiple countries, Gb Sciences team are working to move quickly through the development stages for this novel CRS therapy.

The data presented here document the phytochemical composition of a large dataset of Group III cannabis cultivars and allow for the identification of distinct sub-classes.

Scientific research on breast cancer is still in its early stages, but here we take a look at what we have learned about cannabis to treat breast cancer thus far.

Better seed genetics, power-free tunable lighting, and other new scientific discoveries are making headway in what has become an ag-tech leading industry.

This study presents bioassays for CBD, which can be used to assess the neurotrophic bioactivity of CBD formulations.

David Heldreth, Founder and CEO of Panacea Plant Sciences, discusses the rise in interest in psychedelic medicine and more.

This study offers guidance to establishing meaningful quality standards for the commercialization of cannabis and cannabis-related products.

Here we take an in-depth exploration of the structure, function, and variation of cannabinoid receptor 1 (CB1R).

Dewey Scientific discovers the first powdery mildew resistant gene found in cannabis.

Cannabis’s biggest antagonist is the stigma that surrounds it. Whole plant medicine has the potential to significantly benefit the pharmaceutical industry by complementing their efforts to bring patients relief from their ailments. Systems dynamics consultant/researcher, Ruth Fisher, PhD, explains how cannabis has the option to flourish but needs to stop having its efforts for growth and research hampered by opinions.

An overview of the history regarding medical cannabis as a treatment option for epileptic disorders.

In this interview, Carl Esprey, CEO of Botanical Holdings speaks on the company’s path in the industry, the European cannabis industry and what the US can learn from other countries and more.

This technical piece is focused on the separation of the individual enantiomers of each compound mentioned above, as well as the combined separation of the compounds from each other for a fast, reliable quantification.

Dr. Marion McNabb has been conducting surveys related to medical cannabis for about five years and her most recent endeavor is to gauge the knowledge, interest, and understanding of medical cannabis in healthcare professionals. In this interview, she discusses her latest study as well as her background and key insights into the medical cannabis industry.

A systematic literature review to identify and compare analytical methods used for the determination of cannabinoids in different matrices using LC-based systems.

NFL-NFLPA Joint Pain Management Committee (PMC) plans to award up to $1 million in grants to CBD and cannabis researchers.

In this interview, Maria Enquist-Newman, PhD, Director of R&D Program Management at Demetrix, delves into the specifics of fermentation-produced cannabinoids and how this method can benefit the cannabis industry.

The Cannabis Center of Excellence, Inc., Medicinal Genomics, and UMass Dartmouth have established the Healthcare Provider Knowledge, Attitudes, Practices Related to Medical Cannabis Research Study to help better understand the experiences of healthcare providers have seen with medical cannabis.

Rebecca Jackson discusses a new program at the Maryland Medical Cannabis Commission (MMCC) and what they hope to achieve with it.

As globalization of demand for cannabis and its derivative products increase, new technology and artificial intelligence solutions can greatly boost the output of production and processing.

There’s more hemp out there than the industry knows what to do with.

Professor Edvinas Orentas clears the air surrounding the stigma of synthetic cannabinoids.

Kevin Boehnke, PhD, a research investigator at the Chronic Pain Institute Research Center in the anesthesiology department at the University of Michigan, discusses his research efforts to address questions such as what health conditions are patients using cannabis for, which dosage formats are they using, and does it help chronic pain.

Dr. Walter Wilson discusses NIST's focus on developing cannabis reference materials and a quality assurance program (CannaQAP).

What are the environmental implications of energy consumption for outdoor, indoor, and greenhouse cultivation?

A recent study from University Medical Center Hamburg-Eppendorf Department of Neurology showed promising results in Parkinson's disease patients who used medical cannabis to treat symptoms.

Learn the ways cannabis cultivation uses water as a resource, how to measure and benchmark the key performance indicators (KPIs) for water efficiency and productivity, and the benefits of monitoring, quantifying, and ranking KPIs for water.

Here we discuss issues such as how a repeatable outcome is a critical component of developing cannabis as a reliable medicinal treatment, insight into how to work out extraction goals such as quality terpene development, and more.

This article explores what we do and don’t know about the origins of Cannabis ssp. from a botanical perspective and outlines some of the hypotheses proposed to explain the “why” of cannabinoid production in plants and the approaches that researchers are taking to try and answer this elusive question.